IP Library Granted Patent US 9,750,712
Granted Patent B2
US 9,750,712 · App. 14/649,069 · Granted Sep 5, 2017

Composition and method for treating neuronal ceroid lipofuscinosis

Inventor: Kalipada Pahan (Skokie, IL)
Assignee: Rush University Medical Center
A61K31/216A61K31/192A61K31/203
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,750,712
App. No.
14/649,069
Granted
Sep 5, 2017
Kind
B2
Abstract

Provided herein are methods for treatment of a neurodegenerative disease, such as neuronal ceroid lipofuscinosis including administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of an agent that mediates upregulation of TPP 1.

Claims (11)

1. A method for treatment of a neurodegenerative disease, comprising administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of an agent that mediates upregulation of TPP1, the agent comprising a lipid-lowering drug, wherein the neurodegenerative disease is neuronal ceroid lipofuscinosis, wherein the lipid lowering drug is a fibrate.

2. The method of claim 1 , wherein the fibrate is gemfibrozil or fenofibrate.

3. The method of claim 1 , wherein the neuronal ceroid lipofuscinosis is late infantile neuronal ceroid lipofuscinosis or Batten disease.

4. The method of claim 1 , wherein TPP1 is upregulated by increasing TPP1 mRNA levels, increasing TPP1 protein levels, increasing TPP1 enzymatic activity, or activating a PPAR-RXR heterodimer.

5. The method of claim 1 , wherein the composition further comprises a therapeutically effective amount of all-trans retinoic acid.

6. The method of claim 5 , wherein administering all-trans retinoic acid and a fibrate provides a greater therapeutic effect in the subject than administration of all-trans retinoic acid or the fibrate alone.

7. A method for treatment of a neurodegenerative disease, comprising administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of an agent wherein the agent restores TPP1 activity, the agent comprising a lipid-lowering drug, wherein the neurodegenerative disease is neuronal ceroid lipofuscinosis, wherein the lipid lowering drug is a fibrate.

8. The method of claim 7 , wherein the fibrate is gemfibrozil or fenofibrate.

9. The method of claim 7 , wherein the therapeutically effective amount of the fibrate is lower when the fibrate is administered in combination with all-trans retinoic acid.

10. A method for treatment of neurodegenerative disease, comprising administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of an agent that mediates upregulation of a gene selected from the group of Cln1, Clin2, Cln3, and any combination thereof, the agent comprising a lipid-lowering drug, and wherein the neurodegenerative disease is neuronal ceroid lipofuscinosis, wherein the lipid lowering drug is a fibrate.

11. The method of claim 10 , wherein the fibrate is gemfibrozil or fenofibrate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2015
From: PAHAN, KALIPADA
To: RUSH UNIVERSITY MEDICAL CENTER
Reel/Frame 035792/0959 →
Continuity (2)
Provisional Application 61734679 · Dec 7, 2012
Related Publication 20150313863A1 · Nov 5, 2015